GlobeNewswire Inc | Oct 25, 2021 08:03AM EDT

October 25, 2021

CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.(Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

Catalyst's management team will host a conference call and webcast the following morning, Wednesday, November 10, 2021, at8:30 AM EST to discuss the Company's financial results and provide a corporate update.

Conference Call & Webcast Details

Date/Time: November 10, 2021, at8:30 AM ESTUS/Canada Dial-in Number: (877) 407-8912International Dial- in Number: (201) 689-8059

A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A replay of the webcast will be available on the Catalyst website for 30 days following the date of the event.

AboutCatalyst PharmaceuticalsCatalyst Pharmaceuticalsis a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE(amifampridine) Tablets 10 mg for the treatment of adults with LEMS was approved in 2018 by theU.S. Food & Drug Administration("FDA"), and FIRDAPSEis commercially available inthe United Statesas a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency,Health Canada, approved the use of FIRDAPSEfor the treatment of adult patients inCanadawith LEMS.

FIRDAPSEis currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.

Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with theU.S. Securities and Exchange Commission(SEC), could adversely affect Catalyst. Copies of Catalyst's filings with theSECare available from theSEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.



Media ContactDavid SchullRusso Partners(858) 717-2310david.schull@russopartnersllc.com

Investor ContactMary ColemanCatalyst Pharmaceuticals, Inc.(305) 420-3200mcoleman@catalystpharma.com